{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:05:55Z","timestamp":1783645555968,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.jgar.2015.11.008","type":"journal-article","created":{"date-parts":[[2015,12,23]],"date-time":"2015-12-23T14:02:03Z","timestamp":1450879323000},"page":"11-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Rifaximin combined with polymyxins: A potential regimen for selective decontamination of multidrug-resistant bacteria in the digestive tract?"],"prefix":"10.1016","volume":"4","author":[{"given":"J.W.","family":"Betts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Phee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-5224","authenticated-orcid":false,"given":"D.W.","family":"Wareham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2015.11.008_bib0130","first-page":"21","article-title":"Selective decontamination of the digestive tract: an update of the evidence","volume":"4","author":"Silvestri","year":"2012","journal-title":"HSR Proc Intensive Care Cardiovasc Anesth"},{"key":"10.1016\/j.jgar.2015.11.008_bib0135","first-page":"CD000022","article-title":"Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care","volume":"4","author":"Liberati","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jgar.2015.11.008_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18250","article-title":"Selective decontamination of the digestive tract in critically ill patients treated in intensive care units: a mixed-methods feasibility study (the SuDDICU study)","volume":"18","author":"Francis","year":"2014","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jgar.2015.11.008_bib0145","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2015.11.008_bib0150","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1586\/eri.13.12","article-title":"Clinical relevance of the ESKAPE pathogens","volume":"11","author":"Pendleton","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2015.11.008_bib0155","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/AAC.45.2.643-644.2001","article-title":"In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea","volume":"45","author":"Sierra","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2015.11.008_bib0160","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1365-2036.2007.03259.x","article-title":"High dosage rifaximin for the treatment of small intestinal bacterial overgrowth","volume":"25","author":"Scarpellini","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2015.11.008_bib0165","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/apt.12111","article-title":"Rifaximin in the treatment of recurrent Clostridium difficile infection","volume":"37","author":"Mattila","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jgar.2015.11.008_bib0170","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1017\/S0950268800067169","article-title":"Enterobacteriaceae suppression by three different oral doses of polymyxin E in human volunteers","volume":"100","author":"van Saene","year":"1988","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jgar.2015.11.008_bib0175","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/663206","article-title":"A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage","volume":"33","author":"Saidel-Odes","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2015.11.008_bib0180","first-page":"2375","article-title":"Decolonization of intestinal carriage of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae with oral colistin and neomycin: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Huttner","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2015.11.008_bib0185","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1128\/AAC.00703-13","article-title":"Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Lee","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2015.11.008_bib0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1179\/joc.2003.15.3.235","article-title":"In vitro activity of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa","volume":"15","author":"Giamarellos-Bourboulis","year":"2003","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2015.11.008_bib0195","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zones of diameters. Version 5.0, 2015. EUCAST; 2015. http:\/\/www.eucast.org [accessed 2 December 2015]."},{"key":"10.1016\/j.jgar.2015.11.008_bib0200","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1128\/AAC.00922-10","article-title":"Potent synergy and sustained bactericidal activity of a vancomycin\u2013colistin combination versus multidrug-resistant strains of Acinetobacter baumannii","volume":"54","author":"Gordon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2015.11.008_bib0205","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie Comit\u00e9 de l\u2019Antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie. Recommandations 2012 (Edition de Janvier 2012). SFM; 2012. http:\/\/www.sfm-microbiologie.org\/UserFiles\/files\/casfm\/CASFM_2012.pdf [accessed 2 December 2015]."},{"key":"10.1016\/j.jgar.2015.11.008_bib0210","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antimicrobial wild type distributions of microorganisms. http:\/\/mic.eucast.org\/Eucast2\/SearchController\/search.jsp?action=performSearch&BeginIndex=0&Micdif=mic&NumberIndex=50&Antib=242&Specium=-1 [accessed 17 February 2015]."},{"key":"10.1016\/j.jgar.2015.11.008_bib0215","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/mdr.2011.0010","article-title":"Fitness and molecular mechanisms of resistance to rifaximin in in vitro selected Escherichia coli mutants","volume":"18","author":"Pons","year":"2012","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2015.11.008_bib0220","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/AAC.02163-12","article-title":"Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-\u03b2-naphthylamide-inhibitable efflux pumps","volume":"57","author":"Kothary","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2015.11.008_bib0225","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1128\/JB.01596-14","article-title":"Streptococcus pyogenes polymyxin B-resistant mutants display enhanced ExPortal integrity","volume":"196","author":"Port","year":"2014","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jgar.2015.11.008_bib0230","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jgar.2015.11.008_bib0235","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/499950","article-title":"Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders","volume":"42","author":"Adachi","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2015.11.008_bib0240","doi-asserted-by":"crossref","first-page":"e002529","DOI":"10.1136\/bmjopen-2012-002529","article-title":"Selective decontamination of the digestive tract and selective oropharyngeal decontamination in intensive care unit patients: a cost-effectiveness analysis","volume":"3","author":"Oostdijk","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jgar.2015.11.008_bib0245","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s10096-014-2101-3","article-title":"Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia","volume":"33","author":"Betts","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2015.11.008_bib0250","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1469-0691.2008.02061.x","article-title":"Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies","volume":"14","author":"Petrosillo","year":"2008","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716515001319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716515001319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T12:58:12Z","timestamp":1537102692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716515001319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":25,"alternative-id":["S2213716515001319"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2015.11.008","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifaximin combined with polymyxins: A potential regimen for selective decontamination of multidrug-resistant bacteria in the digestive tract?","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2015.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}